Form 4: MAIA Biotechnology Director Stan Smith Acquires Stock Options

Director Stan Smith reports acquisition of stock options in MAIA Biotechnology, Inc.

Summary

• On June 30, 2024, Stan Smith, a director of MAIA Biotechnology, Inc., acquired 7,160 stock options.
• The options, granted under the company's 2021 Equity Incentive Plan, vest immediately and are exercisable from the grant date.
• The exercise price of the options is $3.42.
• The options expire on June 30, 2034.
• Smith also indirectly owns 7,160 shares of common stock through The Stan V. Smith Trust Dated 1993.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While insider buying can be seen as positive, this is an option grant, which is part of standard compensation.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be informative for investors.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates